Reference
1. Cai J, Yu J, Zhu X, et al. Treatment abandonment in childhood acute
lymphoblastic leukaemia in China: a retrospective cohort study of the
Chinese Children’s Cancer Group. Archives of Disease in
Childhood . 2019;104(6):522-529. doi:10.1136/archdischild-2018-316181
2. Usvasalo A, Savola S, Raty R, et al. CDKN2A deletions in acute
lymphoblastic leukemia of adolescents and young adults: an array CGH
study. Leuk Res . Aug 2008;32(8):1228-1235.
doi:10.1016/j.leukres.2008.01.014
3. Montano A, Forero-Castro M, Marchena-Mendoza D, Benito R,
Hernandez-Rivas JM. New challenges in targeting signaling pathways in
acute lymphoblastic leukemia by NGS approaches: an update. Cancers
(Basel) . Apr 7 2018;10(4):110. doi:10.3390/cancers10040110
4. Bertin R, Acquaviva C, Mirebeau D, Guidal-Giroux C, Vilmer E, Cave H.
CDKN2A, CDKN2B, and MTAP gene dosage permits precise characterization of
mono- and bi-allelic 9p21 deletions in childhood acute lymphoblastic
leukemia. Genes Chromosomes Cancer . May 2003;37(1):44-57.
doi:10.1002/gcc.10188
5. Otsuki T, Clark HM, Wellmann A, Jaffe ES, Raffeld M. Involvement of
CDKN2 (p16ink4A/MTS1) and p15ink4B/MTS2 in human leukemias and
lymphomas. Cancer Research . 1995;55:1436-1440.
6. Mirebeau D, Acquaviva C, Suciu S, et al. The prognostic significance
of CDKN2A, CDKN2B and MTAP inactivation in B-lineage acute lymphoblastic
leukemia of childhood. Results of the EORTC studies 58881 and 58951.haematologica . 2006;91(7):881.
7. Sherborne AL, Hosking FJ, Prasad RB, et al. Variation in CDKN2A at
9p21.3 influences childhood acute lymphoblastic leukemia risk.Nature Genetics . Jun 2010;42(6):492-494. doi:10.1038/ng.585
8. Carter TL, Watt PM, Kumar R, et al. Hemizygous p16(INK4A) deletion in
pediatric acute lymphoblastic leukemia predicts independent risk of
relapse. Blood . Jan 15 2001;97(2):572-4.
doi:10.1182/blood.v97.2.572
9. Kim M, Yim SH, Cho NS, et al. Homozygous deletion of CDKN2A (p16,
p14) and CDKN2B (p15) genes is a poor prognostic factor in adult but not
in childhood B-lineage acute lymphoblastic leukemia: a comparative
deletion and hypermethylation study. Cancer Genetics and
Cytogenetics . Nov 2009;195(1):59-65.
doi:10.1016/j.cancergencyto.2009.06.013
10. Xu N, Li YL, Zhou X, et al. CDKN2 gene deletion as poor prognosis
predictor involved in the progression of adult B-lineage acute
lymphoblastic leukemia patients. Journal of Cancer .
2015;6(11):1114-1120. doi:10.7150/jca.11959
11. Sulong S, Moorman AV, Irving JA, et al. A comprehensive analysis of
the CDKN2A gene in childhood acute lymphoblastic leukemia reveals
genomic deletion, copy number neutral loss of heterozygosity, and
association with specific cytogenetic subgroups. Blood . Jan 1
2009;113(1):100-107. doi:10.1182/blood-2008-07-166801
12. Agarwal M, Bakhshi S, Dwivedi SN, Kabra M, Shukla R, Seth R. Cyclin
dependent kinase inhibitor 2A/B gene deletions are markers of poor
prognosis in Indian children with acute lymphoblastic leukemia.Pediatr Blood Cancer . Jun 2018;65(6):e27001.
doi:10.1002/pbc.27001
13. Kathiravan M, Singh M, Bhatia P, et al. Deletion of CDKN2A/B is
associated with inferior relapse free survival in pediatric B cell acute
lymphoblastic leukemia. Leukemia & Lymphoma . Feb
2019;60(2):433-441. doi:10.1080/10428194.2018.1482542
14. Kees BUR, Burton PR, Lü C, Baker DL. Homozygous deletion of the p16
MTS1 gene in pediatric acute lymphoblastic leukemia is associated with
unfavorable clinical outcome. Blood . 1997;89(11):4161-4166.
15. Einsiedel HG, Taube T, Hartmann R, et al. Deletion analysis of
p16INKa and p15INKb in relapsed childhood acute lymphoblastic leukemia.Blood . 2002;99(12):4629-4631.
16. Malouf C, Ottersbach K. Molecular processes involved in B cell acute
lymphoblastic leukaemia. Cellular and Molecular Life Sciences .
Feb 2018;75(3):417-446. doi:10.1007/s00018-017-2620-z
17. Mohseni M, Uludag H, Brandwein JM. Advances in biology of acute
lymphoblastic leukemia (ALL) and therapeutic implications.American Journal of Blood Research . 2018;8(4):29-56.
18. Wafa A, Aljapawe A, Othman MA, Liehr T, Alhourani E, Achkar WA. Do
novo del(9)(p13) in a childhood T-cell prolymphocytic leukemia as sole
abnormality. Experimental Hematology & Oncology . 2014;3:28.
19. Xerri L, Adélaïde J, Popovici C, et al. CDKN2A/B Deletion and
Double-hit Mutations of the MAPK Pathway Underlie the Aggressive
Behavior of Langerhans Cell Tumors American Journal of Surgical
Pathology . 2017;42(2):150-159.
FIGURE 1 A)co-occurrence of fusion gene in 111 cases of CDKN2A-deleted
ALL;B)co-occurrence of fusion gene in 87 cases of CDKN2A-deleted B-ALL